1. Practice guideline for the therapy of essential thrombocythemia. A statement from the italian Society of Experimental Haematology and the Italian Group for Bone Marrow Transplantation;Barbui;Haematologica,2004
2. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia;Cortelazzo;Journal of Clinical Oncology,1990
3. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia;Harrison;NEJM,2005
4. Final Results of the ANAHYDRET-Study: Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed WHO-Essential Thrombocythemia Patients;Gisslinger;Blood,2008
5. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders;Birgegård;Haematologica,2004